G

Genfit SA
PAR:GNFT

Watchlist Manager
Genfit SA
PAR:GNFT
Watchlist
Price: 4.66 EUR 0.22% Market Closed
Market Cap: 233m EUR

Genfit SA
Income to Minority Interest

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Genfit SA
Income to Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income to Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
G
Genfit SA
PAR:GNFT
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Valneva SE
PAR:VLA
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanobiotix SA
PAR:NANO
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Inventiva SA
PAR:IVA
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cellectis SA
PAR:ALCLS
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
DBV Technologies SA
PAR:DBV
Income to Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genfit SA
Glance View

Market Cap
233m EUR
Industry
Biotechnology

Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.

GNFT Intrinsic Value
5.42 EUR
Undervaluation 14%
Intrinsic Value
Price
G

See Also

Back to Top